#Calcitonin

[er-cryptid]

Calcitonin

[sciencesolutions]

[drpedi07]

Calcitonin Drug

Medical information for Calcitonin on Pediatric Oncall including Mechanism, Indication, Contraindications, Dosing, Adverse Effect, Interaction, Renal Dose, Hepatic Dose.

[deinheilpraktiker]

Der FebriDX Point-of-Care-Immunoassay kann schnell feststellen, ob eine Infektion bakteriell oder viral ist In einem aktuellen JAMA-Netzwerk geöffnet In dieser Studie untersuchen Forscher, ob ein Point-of-Care-Immunoassay namens FebriDx anhand der Werte von Myxovirus-Resistenzprotein A (MxA) und C-reaktivem Protein (CRP) bei akuten Atemwegsinfektionen zwischen bakterien- und virusinduzierten Immunreaktionen bei akuten Atemwegsinfektionen unterscheiden kann. Blutproben entnehmen. Lernen: Diagnostische Genauigkeit eines Point-of-Care-Tests auf bakterielle und virale Biomarker... #Antibiotika_Resistenz #Antibiotikum #Antikörper #Atemwege #Bakterien #Biomarker #BLUT #Bronchitis #C_reaktives_Protein #Calcitonin #Coronavirus #Diagnose #EIWEISS #Entzündung #Epstein_Barr_Virus #Fieber #Grippe #Halsentzündung #Herpes #Herpes_simplex #Herzinfarkt #Husten #Immunisierung #Immunoassay #Immunoglobulin #Immunsuppression #Interferon #Interferone #Kehle #Lungenentzündung #Nasopharyngeal #Operation #Pharyngitis #Polymerase #Polymerase_Kettenreaktion #Rhinorrhoe #SARS #SARS_CoV_2 #Schwere_akute_Atemwegserkrankung #Schweres_akutes_respiratorisches_Syndrom #Sepsis #Sinusitis #Syndrom #Test #Tripper #Verstopfte_Nase #Virus

[jppres]

Epithelial thinning in vaginal atrophy related to lowering of calcitonin gene-related protein, vascular endothelial growth factor, and nerve growth factor expressions in a menopausal rat model

Article published in J. Pharm. Pharmacogn. Res., vol. 11, no. 1, pp. 110-116, January-February 2023. DOI: https://doi.org/10.56499/jppres22.1512_11.1.110 An Nisa Fithri1,2*, Yuyun Yueniwati3, I Wayan Arsana4, Husnul Khotimah5, Wiwit Nurwidyaningtyas6 1Doctoral Program of Medical Sciences, Faculty of Medicine, Universitas Brawijaya, Indonesia. 2Midwifery Program, Sekolah Tinggi Ilmu Kesehatan…

[daicelpharmastandard]

Daicel Pharma manufactures high-quality Calcitonin impurities. We also offer custom synthesis of Calcitonin impurities and supply worldwide.

[reportstore]

Vydura gains positive CHMP nod for migraine, but faces tough competition ahead

Vydura will turn into the primary CGRP receptor adversary accessible in Europe whenever supported by the European Meds Organization (EMA).

On February 25, Biohaven and Pfizer declared that Vydura (rimegepant) had gotten a positive assessment from the European Drugs Organization's (Ema's) Panel for Restorative Items for Human Use (CHMP) in the intense and protection therapy of headache. Whenever endorsed by the EMA, Vydura, which is marketed in the US as Nurtec, will turn into the primary oral calcitonin gene-related peptide (CGRP) type -1 receptor adversary to open up in Europe. Notwithstanding, the medication's market passage will be followed intently by AbbVie's CGRP receptor bad guy, Qulipta (atogepant), which will end up being a savage rival in the headache prophylaxis space.

In spite of a logical first-to-market advantage for Vydura in Europe, GlobalData expects the medication will confront powerful contest from AbbVie's Qulipta, as would be considered normal to enter European markets in 2023. Key assessment pioneers (KOLs) talked with by GlobalData were dazzled with Qulipta's excellent headache avoidance rates and commended its accessibility in three qualities for simple portion titration. Contrasted with Qulipta, Vydura has the additional advantage of both intense and safeguard therapy signs. Notwithstanding, KOLs noticed that gepants had restricted utility in the intense therapy of headache. They made sense of that gepants are generally very delayed in their beginning of activity, and are subsequently less ideal for intense relief from discomfort, especially when contrasted with reasonable generic triptans. In light of these variables, GlobalData gauges Vydura and Qulipta to arrive at deals of $35.4 million and $57.1 million, separately, by 2030 in the five significant European markets (5EU) (France, Germany, Italy, Spain, and the UK).

For more CALCRL Pipeline Products Market mechanisms of action insights, download a free report sample

Across the seven significant pharmaceutical markets (7MM) (US, 5EU, and Japan), GlobalData expects headache market deals of $652.1 million for Nurtec/Vydura in 2030, addressing almost 22% of complete deals inside the developing oral CGRP inhibitor class. Probable in a bid to separate it from contenders, Biohaven has plans for Nurtec/Vydura beyond the nervous system science space. In January 2021, as a team with Weill Cornell Clinical School , the organization began a Stage II pilot investigation of Nurtec in the treatment of plaque psoriasis. All the more as of late, the organization reported the beginning of another Stage II/III preliminary (NCT05248997) of Nurtec in the therapy of persistent rhinosinusitis. These two illness markets are sizeable and could enormously expand Nurtec's range in the event that the medication is viewed as solid.

[ashleyrowanthewriter]

The Sign for Gold Is Ugly - Chapter 1

Next

*************

It began as a routine blood test. Goldie was impatiently rocking in her chair and flapping her tail that was beginning to grow while Dr. Erian was reading her card. From time to time he was glancing at his patient only to return to reading the card. Finally he put it down on his desk.

“I have some good news and some bad news,” said Dr. Erian.

“Some good news? What about?” asked Goldie.

“The good news is that your levels of calcitonin have finally reached the level that allows you to be legally deemed a merfolk,” said Dr. Erian.

Hearing the diagnosis Goldie became ecstatic. She threw her hands in the air and squealed through a toothy grin.

“That’s so great!” Goldie said. “What do I need to sign?”

“Not so fast,” said Dr. Erian. “I know how exciting that might sound, but you still have some paperwork not done.”

Goldie stopped her excited rocking and looked at Dr. Erian.

“What do you mean paperwork?” Goldie was shocked. “I have everything covered! Your psychiatric approval, the two year life test and even the single status certificate! And you just said that I have perfect hormone levels! What else would I need?”

“Well, you seem to have forgotten about the Mermaid Sign Language certificate, didn’t you?” said Dr. Erian

Goldie looked as if she heard about it for the first time.

“That’s a requirement?” asked Goldie. “Last time I checked it was just advice!”

“Times change quickly when you do animal HRT,” said Dr. Erian.

“How quickly are we speaking exactly?”

“I guess 30 months is a long time, isn’t it? From the beginning of it all to now.”

“But don’t they say that law doesn’t work backwards?”

“It doesn't. You haven’t started your legal procedure so you still don’t transition using the old system.”

Goldie wanted to protest, but she ran out of arguments. She just crossed her hands and frowned. Dr. Erian looked for something inside the drawer of his desk.

“Try going to her,” Dr. Erian told Goldie. “My other patients say that they achieve great results with her.”

Saying that Dr. Erian pulled out a flyer from his desk. Goldie read it with curiosity. In the picture there was a human woman and a beautiful mermaid with a gorgeous lingcod tail. They were raising their right hands and spreading their fingers. The description read Dr. Rowan’s Merslan School - For transitioners and translators.

Goldie thought that maybe she could try. Not that she particularly trusted Erian’s claims of satisfied patients. She simply saw no better alternative.

It was Goldie’s first class at Dr. Rowan’s school. She looked around the classroom looking at all the fellow students. Some were early into their transition, some were in a similar stage to her and some already had to be using wheelchairs thanks to their progress. All of them gathered in that room in a common goal to learn that one peculiar skill that the law found mandatory for them. For a moment it gathered up some self esteem in Goldie. If so many people were trying to do it then for sure Goldie could do it.

The door opened and one more person went in. A tall woman holding a briefcase. She stood before the class, raised her right hand and spread her fingers. The class repeated her movements. Goldie was confused, but she made the sign as well. She was waiting for the woman to sit down with the rest of the class, but then she started speaking.

“Alright, good morning, class! It is delightful to see you all. I am Dr. Rowan, but you might already know that. I am excited about teaching you and I hope you’re excited about learning with me.”

Goldie couldn’t believe what she heard. She took out the flyer from Dr. Erian, looking at it and at her teacher. There was no doubt. It was the human from the picture. It was strange for Goldie. She was almost sure that the teacher should be some kind of mermaid. Wasn’t there a mermaid on the flyer? Was that just a student? But it was only natural to think otherwise. Assumptions are indeed a powerful light that can blind its wielder.

The first lesson was feeling longer and longer and slower and slower. As much as she wanted to, she understood very little of whatever Dr. Rowan tried to teach her class. Goldie wanted the class to end. She wanted to once again understand what her senses were registering. Sure, she caught the meaning of maybe five signs, but she completely missed about fifteen others.

Near the end of the lesson Dr. Rowan finally said something that Goldie could understand.

“Now, one more thing before we finish. As you might have guessed, the names used in the Mermaid Language are not names you may be familiar with from English.After all there is no real way of communicating them through its signs. Instead you can choose any sign you’d like to!”

Finally Goldie caught something and found it cool.

“So I want you to think about whatever word you’d like to use as your name and tell me next week,” said Dr. Rowan. “I’ll show you how to show it. And… That’s all for today!”

Of course Goldie already knew what sign she wanted to use. So while her classmates were leaving the class she instead went to Dr. Rowan.

“Excuse me, what if I already have a word I want to use?” asked Goldie.

Dr. Rowan smiled. “I’ll show you then. What should it be?”

“Gold,” said Goldie. “Well… It might have been kind of obvious,” she added and chuckled.

“Alright, it’s easy. Look,” said Dr. Rowan.

The teacher closed her left eye and brought her right hand to her right eye. She then brought her thumb, index and middle finger together.

“Like this,” said Dr. Rowan.

Goldie mimicked her movements. She found the sign disappointing. She kind of hoped it would be more beautiful.

In her house Goldie was practising her name in front of a mirror. Or something along the lines. She had very mixed feelings about it. Her sister, Kayla, who just came to visit Goldie, noticed her lost in the mirror.

“Did something happen?” asked Kayla.

“The sign for gold is ugly,” said Goldie, still lost in her practice.

Kayla remembered that Goldie told her about trying to learn the Mermaid language. It was the first time she saw her sister practising and she saw that she did not have a fun time.

“Trouble learning?” Kayla asked.

“No kidding,” said Goldie. “Once I remember some sign I forget it immediately.”

“Don’t worry, you’re gonna be great at it someday,” said Kayla.

“It would be nice,” said Goldie. “But I guess this is my hell.”

Goldie returned to training signs. Kayla stood behind her and looked at Goldie’s reflection. She was still attempting to practise.

Kayla moved her sight to her own reflection. She was on her way to transition into a bat, but she didn’t know how far she would want to push her transition. She already had a lot of bat traits that she loved. Cute fur, wings beginning to sprout, sensitive ears… Kayla focused on her ears. They were really sensitive. In loud environments they were really hurting her. She sometimes needed to wear silencers.

And maybe that was the way to give Goldie some motivation and faith…

“You know…,” Kayla said. “Sometimes I do wish to be able to turn my hearing off.”

“Don’t you have silencers?” asked Goldie.

“Yes, but… I can’t talk if I can’t hear,” said Kayla. “I would like to learn some sign language. Maybe you could teach me?”

At first Goldie thought that she could help Kayla a bit. After all, who was she not to help her own sister? But then she noticed the possible hidden intentions.

“Is that supposed to make me want to study harder?” said Goldie.

“Maybe,” said Kayla.

Goldie sighed and laughed.

“Alright, sis!” Goldie said. “I can’t promise anything, but whatever I get I’ll try to teach you.”

“Thank you!” said Kayla. “Maybe you’ll manage to actually pick stuff up easier!”

“Yeah,” said Goldie. “Let’s hope so.”

*************

Yup, I am writing a fanfic of the Furry HRT universe. I wanted to come back to the idea. And write a story about aspiring mermaids learning sign language. As you might have guessed the main character is going to be @welldrawnfish. Also @kaylasartwork is going to be featured. I hope they like it!

EDIT: Thought I actually should link to Goldie's fish story and Kayla's bat story. Whoopsies...

[qwertyfingers]

Two cool migraine-related papers i found today:

CGRP has a direct biochemical effect on anxiety. Relevant because migraine patients (sometimes! there are multiple pathologies involved in migraine and not everyone is the same) have significantly elevated serum CGRP compared to healthy controls

2. Migraine patients on CGRP antibody treatments see improvements in depressive symptoms independent of the effect on their migraines

The second study is a small group and the numbers aren't super impressive but it matches up with my experience from the patient side and pretty cool to see work being done on this!

[creative-anchorage]

Why are women more likely than men to suffer from fibromyalgia, osteoarthritis, irritable bowel syndrome, and other chronic pain conditions?   Various theories have been proposed over the years, such as gender bias in healthcare, the lingering effects of childhood trauma, and women “catastrophizing” about their pain more than men. Now there’s a new theory, which could radically change how men and women are treated for pain. In a groundbreaking study published in the journal BRAIN, researchers at University of Arizona Health Sciences identified two substances – prolactin and orexin B – that appear to make mice, monkeys and humans more sensitized to pain. Prolactin is a hormone that promotes breast development and lactation in females; while orexin B is a neurotransmitter that helps keep us awake and stimulates appetite. Both males and females have prolactin and orexin, but females have much higher levels of prolaction and males have more orexin.  In addition to promoting lactation and wakefulness, both substances also appear to play a role in regulating nociceptors, specialized nerve cells near the spinal cord that produce pain when they are activated by a disease or injury. “Until now, the assumption has been that the driving mechanisms that produce pain are the same in men and women,” says Frank Porreca, PhD, research director of the Comprehensive Center for Pain & Addiction at UA Health Sciences. “What we found is that the basic, underlying mechanisms that result in the perception of pain are different in male and female mice, in male and female nonhuman primates, and in male and female humans.” Porreca and his colleagues made their discovery while researching the relationship between chronic pain and sleep.  Using tissue samples from male and female mice, rhesus monkeys and humans, they found that prolactin only sensitizes nociceptors in females, regardless of species, while orexin B only sensitizes the nociceptors of males. The research team then tried blocking prolactin and orexin B signaling, and found that blocking prolactin reduced nociceptor activation only in female cells, while blocking orexin B only affected the nerve cells of males. In effect, they found that there are distinctive “male” and “female” nociceptors.   “The nociceptor is actually different in men and women, different in male and female rodents, and different in male and female non human primates. That’s a remarkable concept, because what it's really telling us is that the things that promote nociceptive sensitization in a man or a woman could be totally different,” Porreca told PNN. “These are two mechanisms that we identified, but there are likely to be many, many more that have yet to be identified.” Once such mechanism could be calcitonin gene-related peptides (CGRPs), a protein that binds to nerve receptors in the brain and trigger migraine pain. In a recent study, Porreca suggested that sexual differences may be the reason why migraine drugs that block CGRPs are effective in treating migraine pain in women, but are far less effective in men.   Until these differences are more fully understood, Porreca says clinical trials should be designed to have an equal number of men and women. That way differences between the sexes could be more easily recognized and applied in clinical practice. For example, therapies that block prolactin may be an effective way to treat fibromyalgia in women, while drugs that block orexin B might be a better way to treat certain pain conditions in men. “We have an opportunity to develop therapies that could be more effective in treating pain in a man or in a woman than the generalized kinds of therapies that we use now,” said Porreca. ‘I think it's critically important that these pain syndromes really be taken very seriously. And that we find better ways of treating female pain and also male pain.” 

[lifewithchronicpain]

German scientists may have finally proven a link between hormones and migraines, and why women suffer migraines at triple the rate that men do. In studies on animals and humans, researchers found that calcitonin gene-related peptides (CGRPs) increase in females during menstruation.

CGRP is a protein that binds to nerve receptors and dilates blood vessels in the brain, causing migraine pain. Several medications are now on the market that inhibit CGRP, one of the biggest innovations in migraine treatment in decades.

“This elevated level of CGRP following hormonal fluctuations could help to explain why migraine attacks are more likely during menstruation and why migraine attacks gradually decline after menopause,” says Bianca Raffaelli, MD, of Charité – Universitätsmedizin Berlin in Germany. “These results need to be confirmed with larger studies, but we’re hopeful that they will help us better understand the migraine process.”

Raffaelli and her colleagues measured CGRP levels in the blood and tear fluid of 180 women during their menstrual cycles, and found that those who suffer from episodic migraines had significantly higher concentrations of CGRP during menstruation, when estrogen levels are low. (Read more at link)

[munaeem]

Fatigue, feeling cold and dry skin are symptoms of hypothyroidism (underactive thyroid)

The thyroid gland is placed in the front center of the neck, between the trachea and the larynx. It is the organ that produces the hormones triiodothyronine (T3), thyroxine (T4), and calcitonin. The thyroid requires iodine from the diet and the environment to manufacture it. The pituitary gland produces the hormone TSH, which regulates thyroid function. Hypothyroidism (hypothyroidism) is a group…

[preventmigraine]

How CGPR Related to Migraine?

Migraine is a disabling neurological disease with symptoms that include moderate or severe unilateral or bilateral headache, nausea/vomiting, sensitivity to light, noise, and/or smells. Migraine CME is essential to understanding the relationship between CGRP and migraine. CGRP, or calcitonin gene-related peptide, is a neuropeptide that plays a crucial role in migraine pathophysiology.

[snowandstarlight]

okay i mostly use this tag to complain but i figured i’d contribute something semi-educational for once

i’m sure I’m not the first one to think of this (the first one is straight from First Aid), but here’s how i remember the different Multiple Endocrine Neoplasias

MEN I - Ps

     Parathyroid hyperplasia

     Pituitary adenomas

     Pancreatic neuroendocrine tumors

MEN IIa - Cs

     Medullary thyroid cancer (from parafollicular C cells, secretes Calcitonin)

     Parathyroid hyperplasia (elevated Calcium)

     Pheochromocytoma (produces Catecholamines)

MEN IIb - Ms

      Medullary thyroid cancer

     Pheochromocytoma (diagnosed with elevated plasma Metanephrines)

     Marfanoid habitus

     Mucosal neuromas

[mordormr]

Insights into the Migraine Therapeutics Industry: Trends, Growth, and Future Outlook 

The global migraine therapeutics market is projected to grow from USD 6.16 billion in 2024 to USD 8.58 billion by 2029, registering a compound annual growth rate (CAGR) of 6.84% during the forecast period (2024-2029).  

Migraine, a debilitating neurological condition affecting millions globally, has spurred significant advancements in therapeutic solutions. The migraine therapeutics industry has witnessed robust growth driven by increased awareness, innovation in drug development, and a focus on personalized medicine. Let’s dive into the key aspects shaping the industry and what lies ahead. 

Market Growth Drivers 

Rising Prevalence of Migraines: Migraine affects over 10% of the global population, with women being disproportionately impacted. As awareness about the condition increases, more people are seeking medical intervention, boosting demand for effective therapeutics. 

Advancements in Drug Development: Innovative therapies such as calcitonin gene-related peptide (CGRP) inhibitors have revolutionized migraine treatment. These drugs, designed to prevent and treat migraines, have seen widespread adoption due to their efficacy and fewer side effects compared to traditional treatments. 

Focus on Preventive Therapies: With a shift towards prevention rather than symptomatic treatment, the industry has seen a rise in prophylactic medications. These solutions aim to reduce the frequency and severity of migraines, improving patients' quality of life. 

Personalized Medicine and Biotechnology Integration: Biotechnology advancements have enabled personalized approaches to migraine treatment. Genetic profiling and biomarkers are now guiding tailored therapies, ensuring better patient outcomes. 

Key Trends in the Industry 

Emerging Digital Therapeutics: Digital platforms, including wearable devices and mobile applications, are playing a pivotal role in managing migraines. These tools track triggers, symptoms, and treatment effectiveness, offering data-driven insights for both patients and healthcare providers. 

Innovative Delivery Systems: Non-invasive drug delivery systems, such as nasal sprays and auto-injectors, are gaining traction for their ease of use and rapid onset of action, especially for acute migraine episodes. 

Collaborations and Partnerships: Pharmaceutical companies are increasingly collaborating with research institutions and biotech firms to accelerate the development of novel migraine therapies. 

Challenges in the Migraine Therapeutics Market 

High Cost of Treatment: Advanced therapeutics like CGRP inhibitors come at a premium, posing affordability issues, especially in low-income regions. 

Diagnostic Challenges: Despite advancements, migraines remain underdiagnosed due to overlapping symptoms with other neurological conditions, delaying effective treatment. 

Regulatory Hurdles: Gaining regulatory approval for novel therapeutics is a time-intensive and costly process, impacting the pace of new drug introductions. 

Future Outlook 

The migraine therapeutics market is poised for exponential growth in the coming years. Key factors driving this growth include: 

Continued Innovation: Pipeline drugs, including oral CGRP antagonists and gene therapy, promise to redefine migraine management. 

Market Expansion: Emerging markets in Asia-Pacific, Latin America, and the Middle East are witnessing increasing demand for advanced therapeutics due to improved healthcare infrastructure. 

Integration of AI in Drug Discovery: Artificial Intelligence (AI) is being leveraged to expedite the discovery of novel compounds, reducing time-to-market for new therapies. 

Conclusion 

The migraine therapeutics industry is at the forefront of addressing a widespread and impactful condition. With ongoing innovation and a patient-centered approach, the industry is set to achieve remarkable milestones in improving migraine management and patient outcomes. However, addressing cost, accessibility, and awareness challenges will be critical for sustained growth and global impact. 

Whether you're a healthcare provider, pharmaceutical professional, or patient, the migraine therapeutics market offers promising advancements that could redefine treatment paradigms in the years to come. 

For a detailed overview and more insights, you can refer to the full market research report by Mordor Intelligence https://www.mordorintelligence.com/industry-reports/migraine-therapeutics-market